Annex 1 — sterile medicinal products

The revised Annex 1 was published in August 2022 and came into operation on 25 August 2023, with the provision on lyophilisation applying from 25 August 2024. The change was not cosmetic. The revision substantially expanded expectations and reorganised them around quality risk management and a contamination control strategy that must be assessed for effectiveness rather than merely written.

The CCS is where most sites are weakest, and the reason is structural. A CCS is not a document that lists which SOPs exist. It is a strategy: a site-wide assessment of contamination sources — microbial, particulate and pyrogen — the controls applied to each, and evidence that the controls, taken together, work. A compilation of cross-references to existing procedures is the most common form this takes and the most straightforward for an inspector to dismantle.

The annex also raised expectations on barrier technology, environmental monitoring design, aseptic process simulation and personnel. Environmental monitoring in particular is expected to be designed from a contamination risk assessment rather than from historical sampling locations, with the programme justified by where risk actually sits and trend data interpreted rather than merely collected.

The practical difficulty for small and mid-size sterile sites is that Annex 1 raised the bar without raising headcount. That makes prioritisation the real skill: identifying which gaps carry genuine patient risk and sequencing the rest honestly, rather than attempting everything at once and finishing none of it.